MET fusions are primary drivers of tumor growth in multiple tumor types—lung cancer and gliomas—and can be effectively targeted with either type I (crizotinib, capmatinib, tepotinib, and savolitinib) or type II (cabozantinib) MET TKIs, with best responses in tumors harboring fusions with partner homodimerization [229]. This evidence concerns the gene MET and central nervous system cancer.